OBJECTIVE: The purpose of this study was to complete an evaluation of nevirapine (NVP) toxicity in a cohort of HIV+ pregnant women. STUDY DESIGN: This was a retrospective study of 611 women followed from January 1996 to December 2003. All women who used NVP for > 7 days were included. Multivariate logistic regression was used to test independent association of CD4 and hepatitis C virus (HCV) infection related to the outcome of toxic effects of NVP. RESULTS: One hundred ninety-seven women were exposed to NVP for > 7 days, and toxicity occurred in 11 (5.6%), leading to drug discontinuation in 7 patients. One case of Stevens-Johnson syndrome occurred. No serious liver toxicity occurred except for 1 grade 4 cholestasis. Median CD4 was 344 in women without toxicities and 298 in women with toxicities. HCV was the only significant factor associated to toxicity by logistic regression (odds ratio [OR] 15.61, P = .001). CONCLUSION: NVP toxicities occurred in a very small fraction of patients and were not associated with fatalities.
OBJECTIVE: The purpose of this study was to complete an evaluation of nevirapine (NVP) toxicity in a cohort of HIV+ pregnant women. STUDY DESIGN: This was a retrospective study of 611 women followed from January 1996 to December 2003. All women who used NVP for > 7 days were included. Multivariate logistic regression was used to test independent association of CD4 and hepatitis C virus (HCV) infection related to the outcome of toxic effects of NVP. RESULTS: One hundred ninety-seven women were exposed to NVP for > 7 days, and toxicity occurred in 11 (5.6%), leading to drug discontinuation in 7 patients. One case of Stevens-Johnson syndrome occurred. No serious liver toxicity occurred except for 1 grade 4 cholestasis. Median CD4 was 344 in women without toxicities and 298 in women with toxicities. HCV was the only significant factor associated to toxicity by logistic regression (odds ratio [OR] 15.61, P = .001). CONCLUSION: NVP toxicities occurred in a very small fraction of patients and were not associated with fatalities.
Authors: Ylva Terelius; Robert A Figler; Svetlana Marukian; Maria S Collado; Mark J Lawson; Aaron J Mackey; David Manka; Charles W Qualls; Brett R Blackman; Brian R Wamhoff; Ajit Dash Journal: Chem Biol Interact Date: 2015-12-02 Impact factor: 5.192
Authors: June M McKoy; Charles L Bennett; Marc H Scheetz; Virginia Differding; Kevin L Chandler; Kimberly K Scarsi; Paul R Yarnold; Sarah Sutton; Frank Palella; Stuart Johnson; Eniola Obadina; Dennis W Raisch; Jorge P Parada Journal: Drug Saf Date: 2009 Impact factor: 5.606
Authors: David W Ouyang; Susan B Brogly; Ming Lu; David E Shapiro; Ronald C Hershow; Audrey L French; Robert M Leighty; Bruce Thompson; Ruth E Tuomala Journal: AIDS Date: 2010-01-02 Impact factor: 4.177
Authors: Carlo Torti; Silvia Costarelli; Annalisa De Silvestri; Eugenia Quiros-Roldan; Giuseppe Lapadula; Giuliana Cologni; Giuseppe Paraninfo; Filippo Castelnuovo; Massimo Puoti; Giampiero Carosi Journal: Drug Saf Date: 2007 Impact factor: 5.606
Authors: Susie Huntington; Claire Thorne; Marie-Louise Newell; Jane Anderson; Graham P Taylor; Deenan Pillay; Teresa Hill; Pat A Tookey; Caroline Sabin Journal: AIDS Date: 2015-04-24 Impact factor: 4.177